• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 2010 ASH_SGI-110 Preclinical, PK, DNA Methylation of Low Vol Subcutaneous...

2010 ASH_SGI-110 Preclinical, PK, DNA Methylation of Low Vol Subcutaneous Formulation

25 July 2010/in Uncategorised

2010 ASH_SGI-110 Preclinical, PK, DNA Methylation of Low Vol Subcutaneous Formulation

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2010-07-25 16:03:122016-12-01 12:35:342010 ASH_SGI-110 Preclinical, PK, DNA Methylation of Low Vol Subcutaneous Formulation

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Dacogen® (Decitabine) for Injection Phase III AML Results Announced Link to: Dacogen® (Decitabine) for Injection Phase III AML Results Announced Dacogen® (Decitabine) for Injection Phase III AML Results Announced Link to: Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry Link to: Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry Astex scientists describe novel HSP90 inhibitors in two key publications in...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok